文献速递先天性心脏病外科心外重症与机械循环支持

HLHS患者HYBRID+VAD支持后的心脏移植:技术考量与结局

Cardiac Transplantation After HYBRID+VAD Support in Patients With HLHS: Technical Considerations and Outcomes.
PubMed 文献 · Ann Thorac Surg · 2025-07-09

本研究回顾了7例功能单心室导管依赖性体循环婴儿在HYBRID+VAD支持后接受心脏移植的经验。所有7例均成功完成移植,随访中位3.9年全部存活且状况良好,无患者需再干预主动脉或肺动脉。结论认为HYBRID+VAD后心脏移植安全有效,短期和中期结局优异。

要点

  • HYBRID+VAD可作为高危HLHS婴儿桥接移植的有效策略。
  • 移植术中仅需主动脉弓重建和简单去除并扩张肺动脉环扎,无需肺动脉补片。
  • 7例移植后中位随访3.9年全部存活,无主动脉或肺动脉再干预。

核心结论

  • HYBRID+VAD支持后的心脏移植可安全有效地实施,并带来优异的短期和中期结局。

主要发现

  • VAD支持中位154天(范围64-226天),移植时中位年龄177天(范围84-250天)。
  • 7例中6例(85.7%)为ABO血型不合移植。
  • 所有7例均成功完成移植,包括主动脉弓重建和简单去除并扩张肺动脉环扎,无患者需肺动脉补片。
  • 体外循环时间中位169分钟(范围139-208), cross-clamp时间中位89分钟(范围56-116), antegrade cerebral perfusion时间中位29分钟(范围24-39),供体缺血时间中位212分钟(范围139-236)。
  • 移植后中位住院26天(范围8-43天),1例出现声带功能障碍并接受胃造瘘,随访中位3.9年(范围2.2-7.1年)全部存活且状况良好。

临床怎么用

  • 对于高危HLHS婴儿,可考虑HYBRID+VAD作为桥接移植策略,移植术中主动脉弓重建和简单去除肺动脉环扎即可,无需常规肺动脉补片。

局限性

  • 样本量小(7例移植),为单中心回顾性分析,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-risk patients with hypoplastic left heart syndrome can be supported with combined Hybrid Stage 1 (arterial duct stenting, bilateral pulmonary artery banding, and atrial septectomy if needed) and ventricular assist device (VAD) insertion (HYBRID+VAD) as a bridge to transplantation. Concerns have been raised about the challenges and complexity of the subsequent cardiac transplantation. The purpose of this analysis was to review the investigators' experience with 7 consecutive infants with functionally univentricular ductal-dependent systemic circulation who underwent cardiac transplantation after HYBRID+VAD. METHODS: Ten consecutive high-risk neonates with functionally univentricular ductal-dependent systemic circulation and major cardiac risk factors were supported with HYRID+VAD, and 7 underwent subsequent cardiac transplantation. The characteristics and outcomes of cardiac transplantation for these 7 patients were reviewed. RESULTS: The median length of VAD support was 154 days (range, 64-226 days). The median age at cardiac transplantation was 177 days (range, 84-250 days). Six of 7 transplants (85.7%) were ABO incompatible. All 7 patients successfully underwent transplantation with aortic arch reconstruction and simple pulmonary artery band removal and dilation. No patients underwent pulmonary artery augmentation at transplantation. Median (range) transplantation times in minutes were as follows: cardiopulmonary bypass time, 169 (139-208); cross-clamp time, 89 (56-116); antegrade cerebral perfusion time, 29 (24-39); and donor ischemic time, 212 (139-236). The minimum temperature was 20.4 °C (range, 19.6-22.8 °C). One patient had posttransplant vocal cord dysfunction and underwent gastrostomy tube insertion. The median posttransplant length of stay was 26 days (range, 8-43 days). No patients have undergone subsequent transcatheter or surgical interventions on their aorta or pulmonary arteries. All 7 patients are currently alive and well, with follow-up after transplantation of 3.9 years (range, 2.2-7.1 years). CONCLUSIONS: Cardiac transplantation after HYBRID+VAD can be performed safely and effectively and results in excellent short-term and midterm outcomes.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Kugler LR, Jacobs JP, Philip J, et al. Cardiac Transplantation After HYBRID+VAD Support in Patients With HLHS: Technical Considerations and Outcomes. Ann Thorac Surg. 2025. PMID: 40645360. doi:10.1016/j.athoracsur.2025.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。